Loading
A phase 2 trial of sacituzumab tirumotecan and bevacizumab in triple-negative breast cancer, run by Fudan University, now recruiting.
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases is a phase 2, interventional study registered as NCT07623577 by Fudan University, with a registry enrolment figure of 24 participants, started 2026-01-01 and due to reach its primary completion in 2027-01. Interventions recorded: Sacituzumab Tirumotecan (Sac-TMT); bevacizumab. Conditions listed: TNBC; Brain Metastasis. Sites: China. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Sacituzumab tirumotecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.